The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Peptide Market Research Report 2025
Synopsis
A recombinant peptide therapy is produced through recombinant DNA technology. This involves inserting the DNA encoding the peptide into bacterial or mammalian cells, expressing the peptide in these cells and then purifying it from them.
The global Recombinant Peptide market was valued at US$ 412 million in 2023 and is anticipated to reach US$ 701.4 million by 2030, witnessing a CAGR of 6.6% during the forecast period 2024-2030.
According to the "Global Use of Medicines 2023" released by IQVIA Institute, global pharmaceutical expenditures in 2022 will be approximately US$1.48 trillion (excluding costs related to COVID vaccines and therapies), and are forecast to grow at a rate of 3%-6% in the next few years. In terms of regional development trends, high-income countries such as Western Europe, North America and Japan are expected to grow at a slower rate in the next few years due to already high per capita usage, while growth markets such as Asia, Latin America and Eastern Europe will grow strongly. In terms of drug spending, China's drug spending in 2022 will be approximately US$166 billion. It is expected that drug expenditures will only increase in the next few years: from the perspective of demand, the trend of population aging, the increase in residents' wealth and the improvement of health awareness will drive the demand for drugs; from the perspective of national strategy, in 2016 , the State Council issued the "Healthy China 2030" Planning Outline, and "Healthy China" has been elevated to a national strategy; from the perspective of industry policies, it has experienced the uncertainty caused by the early stage of pharmaceutical reform, the implementation of centralized procurement policies and the revision of the drug reimbursement catalog The update will gradually achieve a dynamic balance with multiple goals such as promoting innovation, stabilizing supply, and reducing the burden on the public.
This report aims to provide a comprehensive presentation of the global market for Recombinant Peptide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Peptide.
Report Scope
The Recombinant Peptide market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Peptide market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Peptide manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sandoz Pharma
Stada Arzneimittel
Amgen
Hospira
Actavis
Cipla Ltd.
Wockhardt Ltd.
Biocon Ltd.
Segment by Type
Glucagon
Calcitonin
Other
Segment by Application
Oncology
Blood Disorders
Infectious Diseases
Autoimmune Diseases
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Peptide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Peptide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
A recombinant peptide therapy is produced through recombinant DNA technology. This involves inserting the DNA encoding the peptide into bacterial or mammalian cells, expressing the peptide in these cells and then purifying it from them.
The global Recombinant Peptide market was valued at US$ 412 million in 2023 and is anticipated to reach US$ 701.4 million by 2030, witnessing a CAGR of 6.6% during the forecast period 2024-2030.
According to the "Global Use of Medicines 2023" released by IQVIA Institute, global pharmaceutical expenditures in 2022 will be approximately US$1.48 trillion (excluding costs related to COVID vaccines and therapies), and are forecast to grow at a rate of 3%-6% in the next few years. In terms of regional development trends, high-income countries such as Western Europe, North America and Japan are expected to grow at a slower rate in the next few years due to already high per capita usage, while growth markets such as Asia, Latin America and Eastern Europe will grow strongly. In terms of drug spending, China's drug spending in 2022 will be approximately US$166 billion. It is expected that drug expenditures will only increase in the next few years: from the perspective of demand, the trend of population aging, the increase in residents' wealth and the improvement of health awareness will drive the demand for drugs; from the perspective of national strategy, in 2016 , the State Council issued the "Healthy China 2030" Planning Outline, and "Healthy China" has been elevated to a national strategy; from the perspective of industry policies, it has experienced the uncertainty caused by the early stage of pharmaceutical reform, the implementation of centralized procurement policies and the revision of the drug reimbursement catalog The update will gradually achieve a dynamic balance with multiple goals such as promoting innovation, stabilizing supply, and reducing the burden on the public.
This report aims to provide a comprehensive presentation of the global market for Recombinant Peptide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Peptide.
Report Scope
The Recombinant Peptide market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Peptide market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Peptide manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sandoz Pharma
Stada Arzneimittel
Amgen
Hospira
Actavis
Cipla Ltd.
Wockhardt Ltd.
Biocon Ltd.
Segment by Type
Glucagon
Calcitonin
Other
Segment by Application
Oncology
Blood Disorders
Infectious Diseases
Autoimmune Diseases
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Peptide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Peptide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Recombinant Peptide Market Overview
1.1 Product Overview and Scope of Recombinant Peptide
1.2 Recombinant Peptide Segment by Type
1.2.1 Global Recombinant Peptide Market Value Comparison by Type (2024-2030)
1.2.2 Glucagon
1.2.3 Calcitonin
1.2.4 Other
1.3 Recombinant Peptide Segment by Application
1.3.1 Global Recombinant Peptide Market Value by Application: (2024-2030)
1.3.2 Oncology
1.3.3 Blood Disorders
1.3.4 Infectious Diseases
1.3.5 Autoimmune Diseases
1.3.6 Other
1.4 Global Recombinant Peptide Market Size Estimates and Forecasts
1.4.1 Global Recombinant Peptide Revenue 2019-2030
1.4.2 Global Recombinant Peptide Sales 2019-2030
1.4.3 Global Recombinant Peptide Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Peptide Market Competition by Manufacturers
2.1 Global Recombinant Peptide Sales Market Share by Manufacturers (2019-2024)
2.2 Global Recombinant Peptide Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Recombinant Peptide Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant Peptide Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Peptide, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Peptide, Product Type & Application
2.7 Recombinant Peptide Market Competitive Situation and Trends
2.7.1 Recombinant Peptide Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Peptide Players Market Share by Revenue
2.7.3 Global Recombinant Peptide Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Peptide Retrospective Market Scenario by Region
3.1 Global Recombinant Peptide Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Peptide Global Recombinant Peptide Sales by Region: 2019-2030
3.2.1 Global Recombinant Peptide Sales by Region: 2019-2024
3.2.2 Global Recombinant Peptide Sales by Region: 2025-2030
3.3 Global Recombinant Peptide Global Recombinant Peptide Revenue by Region: 2019-2030
3.3.1 Global Recombinant Peptide Revenue by Region: 2019-2024
3.3.2 Global Recombinant Peptide Revenue by Region: 2025-2030
3.4 North America Recombinant Peptide Market Facts & Figures by Country
3.4.1 North America Recombinant Peptide Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Peptide Sales by Country (2019-2030)
3.4.3 North America Recombinant Peptide Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Peptide Market Facts & Figures by Country
3.5.1 Europe Recombinant Peptide Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Peptide Sales by Country (2019-2030)
3.5.3 Europe Recombinant Peptide Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Peptide Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Peptide Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Peptide Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant Peptide Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Peptide Market Facts & Figures by Country
3.7.1 Latin America Recombinant Peptide Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Peptide Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Peptide Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Peptide Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Peptide Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Peptide Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Peptide Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Peptide Sales by Type (2019-2030)
4.1.1 Global Recombinant Peptide Sales by Type (2019-2024)
4.1.2 Global Recombinant Peptide Sales by Type (2025-2030)
4.1.3 Global Recombinant Peptide Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Peptide Revenue by Type (2019-2030)
4.2.1 Global Recombinant Peptide Revenue by Type (2019-2024)
4.2.2 Global Recombinant Peptide Revenue by Type (2025-2030)
4.2.3 Global Recombinant Peptide Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Peptide Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Peptide Sales by Application (2019-2030)
5.1.1 Global Recombinant Peptide Sales by Application (2019-2024)
5.1.2 Global Recombinant Peptide Sales by Application (2025-2030)
5.1.3 Global Recombinant Peptide Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Peptide Revenue by Application (2019-2030)
5.2.1 Global Recombinant Peptide Revenue by Application (2019-2024)
5.2.2 Global Recombinant Peptide Revenue by Application (2025-2030)
5.2.3 Global Recombinant Peptide Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Peptide Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Sandoz Pharma
6.1.1 Sandoz Pharma Corporation Information
6.1.2 Sandoz Pharma Description and Business Overview
6.1.3 Sandoz Pharma Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Sandoz Pharma Recombinant Peptide Product Portfolio
6.1.5 Sandoz Pharma Recent Developments/Updates
6.2 Stada Arzneimittel
6.2.1 Stada Arzneimittel Corporation Information
6.2.2 Stada Arzneimittel Description and Business Overview
6.2.3 Stada Arzneimittel Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Stada Arzneimittel Recombinant Peptide Product Portfolio
6.2.5 Stada Arzneimittel Recent Developments/Updates
6.3 Amgen
6.3.1 Amgen Corporation Information
6.3.2 Amgen Description and Business Overview
6.3.3 Amgen Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Amgen Recombinant Peptide Product Portfolio
6.3.5 Amgen Recent Developments/Updates
6.4 Hospira
6.4.1 Hospira Corporation Information
6.4.2 Hospira Description and Business Overview
6.4.3 Hospira Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Hospira Recombinant Peptide Product Portfolio
6.4.5 Hospira Recent Developments/Updates
6.5 Actavis
6.5.1 Actavis Corporation Information
6.5.2 Actavis Description and Business Overview
6.5.3 Actavis Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Actavis Recombinant Peptide Product Portfolio
6.5.5 Actavis Recent Developments/Updates
6.6 Cipla Ltd.
6.6.1 Cipla Ltd. Corporation Information
6.6.2 Cipla Ltd. Description and Business Overview
6.6.3 Cipla Ltd. Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Cipla Ltd. Recombinant Peptide Product Portfolio
6.6.5 Cipla Ltd. Recent Developments/Updates
6.7 Wockhardt Ltd.
6.6.1 Wockhardt Ltd. Corporation Information
6.6.2 Wockhardt Ltd. Description and Business Overview
6.6.3 Wockhardt Ltd. Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Wockhardt Ltd. Recombinant Peptide Product Portfolio
6.7.5 Wockhardt Ltd. Recent Developments/Updates
6.8 Biocon Ltd.
6.8.1 Biocon Ltd. Corporation Information
6.8.2 Biocon Ltd. Description and Business Overview
6.8.3 Biocon Ltd. Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Biocon Ltd. Recombinant Peptide Product Portfolio
6.8.5 Biocon Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Peptide Industry Chain Analysis
7.2 Recombinant Peptide Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Peptide Production Mode & Process
7.4 Recombinant Peptide Sales and Marketing
7.4.1 Recombinant Peptide Sales Channels
7.4.2 Recombinant Peptide Distributors
7.5 Recombinant Peptide Customers
8 Recombinant Peptide Market Dynamics
8.1 Recombinant Peptide Industry Trends
8.2 Recombinant Peptide Market Drivers
8.3 Recombinant Peptide Market Challenges
8.4 Recombinant Peptide Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Recombinant Peptide Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Recombinant Peptide Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Recombinant Peptide Market Competitive Situation by Manufacturers in 2023
Table 4. Global Recombinant Peptide Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Recombinant Peptide Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Recombinant Peptide Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Recombinant Peptide Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Recombinant Peptide Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Recombinant Peptide, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Recombinant Peptide, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Recombinant Peptide, Product Type & Application
Table 12. Global Key Manufacturers of Recombinant Peptide, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Recombinant Peptide by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Peptide as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Recombinant Peptide Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Recombinant Peptide Sales by Region (2019-2024) & (K Units)
Table 18. Global Recombinant Peptide Sales Market Share by Region (2019-2024)
Table 19. Global Recombinant Peptide Sales by Region (2025-2030) & (K Units)
Table 20. Global Recombinant Peptide Sales Market Share by Region (2025-2030)
Table 21. Global Recombinant Peptide Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Recombinant Peptide Revenue Market Share by Region (2019-2024)
Table 23. Global Recombinant Peptide Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Recombinant Peptide Revenue Market Share by Region (2025-2030)
Table 25. North America Recombinant Peptide Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Recombinant Peptide Sales by Country (2019-2024) & (K Units)
Table 27. North America Recombinant Peptide Sales by Country (2025-2030) & (K Units)
Table 28. North America Recombinant Peptide Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Recombinant Peptide Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Recombinant Peptide Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Recombinant Peptide Sales by Country (2019-2024) & (K Units)
Table 32. Europe Recombinant Peptide Sales by Country (2025-2030) & (K Units)
Table 33. Europe Recombinant Peptide Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Recombinant Peptide Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Recombinant Peptide Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Recombinant Peptide Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Recombinant Peptide Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Recombinant Peptide Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Recombinant Peptide Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Recombinant Peptide Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Recombinant Peptide Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Recombinant Peptide Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Recombinant Peptide Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Recombinant Peptide Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Recombinant Peptide Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Recombinant Peptide Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Recombinant Peptide Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Recombinant Peptide Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Recombinant Peptide Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Recombinant Peptide Sales (K Units) by Type (2019-2024)
Table 51. Global Recombinant Peptide Sales (K Units) by Type (2025-2030)
Table 52. Global Recombinant Peptide Sales Market Share by Type (2019-2024)
Table 53. Global Recombinant Peptide Sales Market Share by Type (2025-2030)
Table 54. Global Recombinant Peptide Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Recombinant Peptide Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Recombinant Peptide Revenue Market Share by Type (2019-2024)
Table 57. Global Recombinant Peptide Revenue Market Share by Type (2025-2030)
Table 58. Global Recombinant Peptide Price (US$/Unit) by Type (2019-2024)
Table 59. Global Recombinant Peptide Price (US$/Unit) by Type (2025-2030)
Table 60. Global Recombinant Peptide Sales (K Units) by Application (2019-2024)
Table 61. Global Recombinant Peptide Sales (K Units) by Application (2025-2030)
Table 62. Global Recombinant Peptide Sales Market Share by Application (2019-2024)
Table 63. Global Recombinant Peptide Sales Market Share by Application (2025-2030)
Table 64. Global Recombinant Peptide Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Recombinant Peptide Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Recombinant Peptide Revenue Market Share by Application (2019-2024)
Table 67. Global Recombinant Peptide Revenue Market Share by Application (2025-2030)
Table 68. Global Recombinant Peptide Price (US$/Unit) by Application (2019-2024)
Table 69. Global Recombinant Peptide Price (US$/Unit) by Application (2025-2030)
Table 70. Sandoz Pharma Corporation Information
Table 71. Sandoz Pharma Description and Business Overview
Table 72. Sandoz Pharma Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Sandoz Pharma Recombinant Peptide Product
Table 74. Sandoz Pharma Recent Developments/Updates
Table 75. Stada Arzneimittel Corporation Information
Table 76. Stada Arzneimittel Description and Business Overview
Table 77. Stada Arzneimittel Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Stada Arzneimittel Recombinant Peptide Product
Table 79. Stada Arzneimittel Recent Developments/Updates
Table 80. Amgen Corporation Information
Table 81. Amgen Description and Business Overview
Table 82. Amgen Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Amgen Recombinant Peptide Product
Table 84. Amgen Recent Developments/Updates
Table 85. Hospira Corporation Information
Table 86. Hospira Description and Business Overview
Table 87. Hospira Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Hospira Recombinant Peptide Product
Table 89. Hospira Recent Developments/Updates
Table 90. Actavis Corporation Information
Table 91. Actavis Description and Business Overview
Table 92. Actavis Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Actavis Recombinant Peptide Product
Table 94. Actavis Recent Developments/Updates
Table 95. Cipla Ltd. Corporation Information
Table 96. Cipla Ltd. Description and Business Overview
Table 97. Cipla Ltd. Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Cipla Ltd. Recombinant Peptide Product
Table 99. Cipla Ltd. Recent Developments/Updates
Table 100. Wockhardt Ltd. Corporation Information
Table 101. Wockhardt Ltd. Description and Business Overview
Table 102. Wockhardt Ltd. Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Wockhardt Ltd. Recombinant Peptide Product
Table 104. Wockhardt Ltd. Recent Developments/Updates
Table 105. Biocon Ltd. Corporation Information
Table 106. Biocon Ltd. Description and Business Overview
Table 107. Biocon Ltd. Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Biocon Ltd. Recombinant Peptide Product
Table 109. Biocon Ltd. Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Recombinant Peptide Distributors List
Table 113. Recombinant Peptide Customers List
Table 114. Recombinant Peptide Market Trends
Table 115. Recombinant Peptide Market Drivers
Table 116. Recombinant Peptide Market Challenges
Table 117. Recombinant Peptide Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Recombinant Peptide
Figure 2. Global Recombinant Peptide Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Recombinant Peptide Market Share by Type in 2023 & 2030
Figure 4. Glucagon Product Picture
Figure 5. Calcitonin Product Picture
Figure 6. Other Product Picture
Figure 7. Global Recombinant Peptide Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Recombinant Peptide Market Share by Application in 2023 & 2030
Figure 9. Oncology
Figure 10. Blood Disorders
Figure 11. Infectious Diseases
Figure 12. Autoimmune Diseases
Figure 13. Other
Figure 14. Global Recombinant Peptide Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Recombinant Peptide Market Size (2019-2030) & (US$ Million)
Figure 16. Global Recombinant Peptide Sales (2019-2030) & (K Units)
Figure 17. Global Recombinant Peptide Average Price (US$/Unit) & (2019-2030)
Figure 18. Recombinant Peptide Report Years Considered
Figure 19. Recombinant Peptide Sales Share by Manufacturers in 2023
Figure 20. Global Recombinant Peptide Revenue Share by Manufacturers in 2023
Figure 21. The Global 5 and 10 Largest Recombinant Peptide Players: Market Share by Revenue in 2023
Figure 22. Recombinant Peptide Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 23. Global Recombinant Peptide Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 24. North America Recombinant Peptide Sales Market Share by Country (2019-2030)
Figure 25. North America Recombinant Peptide Revenue Market Share by Country (2019-2030)
Figure 26. U.S. Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Canada Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Europe Recombinant Peptide Sales Market Share by Country (2019-2030)
Figure 29. Europe Recombinant Peptide Revenue Market Share by Country (2019-2030)
Figure 30. Germany Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. France Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. U.K. Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Italy Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Russia Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Asia Pacific Recombinant Peptide Sales Market Share by Region (2019-2030)
Figure 36. Asia Pacific Recombinant Peptide Revenue Market Share by Region (2019-2030)
Figure 37. China Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Japan Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. South Korea Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. India Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Australia Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Taiwan Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Indonesia Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Thailand Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Malaysia Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Philippines Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Latin America Recombinant Peptide Sales Market Share by Country (2019-2030)
Figure 48. Latin America Recombinant Peptide Revenue Market Share by Country (2019-2030)
Figure 49. Mexico Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Brazil Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Argentina Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Middle East & Africa Recombinant Peptide Sales Market Share by Country (2019-2030)
Figure 53. Middle East & Africa Recombinant Peptide Revenue Market Share by Country (2019-2030)
Figure 54. Turkey Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Saudi Arabia Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. UAE Recombinant Peptide Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. Global Sales Market Share of Recombinant Peptide by Type (2019-2030)
Figure 58. Global Revenue Market Share of Recombinant Peptide by Type (2019-2030)
Figure 59. Global Recombinant Peptide Price (US$/Unit) by Type (2019-2030)
Figure 60. Global Sales Market Share of Recombinant Peptide by Application (2019-2030)
Figure 61. Global Revenue Market Share of Recombinant Peptide by Application (2019-2030)
Figure 62. Global Recombinant Peptide Price (US$/Unit) by Application (2019-2030)
Figure 63. Recombinant Peptide Value Chain
Figure 64. Recombinant Peptide Production Process
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Distributors Profiles
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
